These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30087007)

  • 1. The exploration of population pharmacokinetic model for meropenem in augmented renal clearance and investigation of optimum setting of dose.
    Tamatsukuri T; Ohbayashi M; Kohyama N; Kobayashi Y; Yamamoto T; Fukuda K; Nakamura S; Miyake Y; Dohi K; Kogo M
    J Infect Chemother; 2018 Oct; 24(10):834-840. PubMed ID: 30087007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections.
    Kim YK; Lee DH; Jeon J; Jang HJ; Kim HK; Jin K; Lim SN; Lee SS; Park BS; Kim YW; Shin JG; Kiem S
    Clin Ther; 2018 Aug; 40(8):1384-1395. PubMed ID: 30093133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring.
    Tröger U; Drust A; Martens-Lobenhoffer J; Tanev I; Braun-Dullaeus RC; Bode-Böger SM
    Int J Antimicrob Agents; 2012 Oct; 40(4):370-2. PubMed ID: 22795654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Meropenem-Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance.
    Agyeman AA; Rogers KE; Tait JR; Bergen PJ; Kirkpatrick CM; Wallis SC; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Clin Pharmacol Ther; 2021 Apr; 109(4):1104-1115. PubMed ID: 33550617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Tan WW; Watt KM; Boakye-Agyeman F; Cohen-Wolkowiez M; Mok YH; Yung CF; Chan YH
    J Clin Pharmacol; 2021 Jun; 61(6):744-754. PubMed ID: 33314163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Model and Dosing Simulation of Meropenem Using Measured Creatinine Clearance for Patients with Sepsis.
    Fukumoto S; Ohbayashi M; Okada A; Kohyama N; Tamatsukuri T; Inoue H; Kato A; Kotani T; Sagara H; Dohi K; Kogo M
    Ther Drug Monit; 2023 Jun; 45(3):392-399. PubMed ID: 36253888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.
    Minichmayr IK; Roberts JA; Frey OR; Roehr AC; Kloft C; Brinkmann A
    J Antimicrob Chemother; 2018 May; 73(5):1330-1339. PubMed ID: 29425283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance.
    Jacobs A; Taccone FS; Roberts JA; Jacobs F; Cotton F; Wolff F; Creteur J; Vincent JL; Hites M
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two empirical prolonged infusion dosing regimens for meropenem in patients with septic shock: A two-center pilot study.
    Eisert A; Lanckohr C; Frey J; Frey O; Wicha SG; Horn D; Ellger B; Schuerholz T; Marx G; Simon TP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106289. PubMed ID: 33515688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
    Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
    Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial.
    Udy AA; Dulhunty JM; Roberts JA; Davis JS; Webb SAR; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Paul SK; Lipman J; ;
    Int J Antimicrob Agents; 2017 May; 49(5):624-630. PubMed ID: 28286115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.
    An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Rolsma S; Patel PC; Watanabe A; Fishbane N; Kirkpatrick CMJ; Landersdorfer CB; Winokur P
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0131222. PubMed ID: 36622154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
    Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
    Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients.
    Akers KS; Niece KL; Chung KK; Cannon JW; Cota JM; Murray CK
    J Trauma Acute Care Surg; 2014 Sep; 77(3 Suppl 2):S163-70. PubMed ID: 24770557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
    Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
    Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.